# Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance

> **NCT00752479** · PHASE1,PHASE2 · TERMINATED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 4 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **BIOLOGICAL:** Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil
- **DRUG:** Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT00752479
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2013-07
- **Final completion:** 2013-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Necessity of major revision of the protocol
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752479, "Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00752479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*